(GDC4628g) A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of P13-Kinase Inhibitor GDC-0941 in Combination with either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, and Bevacizumab in Patients with Advanced Non-Small Cell Lung Cancer

The purpose of this study is to find out whether a drug called GDC-0941 can be safely combined with other drug combinations that are already being use for NSCLC patients, paclitaxel and carboplatin (Arm A); paclitaxel, carboplatin, and Bevacizumab (Arm B); and Pemetrexed, Cisplatin, and Bevacizumab (Arm C). Depending on when you enter the study and whether it is safe for you to take Bevacizumab, you may participate in Arm A, B, or Arm C or this study.

Study Number: 

I 155209

Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.